Shilpa Medicare Surges 28% YoY to Record Revenue, Profit Jumps 72%

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Shilpa Medicare Surges 28% YoY to Record Revenue, Profit Jumps 72%
Overview

Shilpa Medicare Limited announced stellar results for Q3 FY26, posting its highest-ever quarterly revenue of ₹411 crore, a significant 28% year-on-year increase. EBITDA grew robustly by 40% to ₹115 crore, with margins expanding by 200 basis points to 28%. Adjusted Profit After Tax (Adj. PAT) surged 72% YoY to ₹55 crore, driven by strong performance in its Formulations vertical, particularly in the EU market, and the launch of its novel NAFLD therapy, NoducaTM, in India. The nine-month period also showed strong growth, with revenue up 14% and Adj. PAT soaring 128% YoY. Management expresses confidence in a "significantly better FY27" with multiple product launches and pipeline advancements expected to fuel further growth and margin improvement.

📉 The Financial Deep Dive

Shilpa Medicare Limited has reported its financial results for the third quarter and nine months ended December 31, 2025 (3Q FY26 and 9M FY26), showcasing a strong performance trajectory.

The Numbers: A Record Quarter

  • 3Q FY26 Performance: The company achieved its highest-ever quarterly revenue at ₹411 crore, marking a substantial 28% increase year-on-year (YoY). EBITDA followed suit, reaching a quarterly high of ₹115 crore, up 40% YoY. This robust top-line growth translated into improved profitability, with EBITDA margins expanding by approximately 200 basis points YoY to 28%. Adjusted Profit After Tax (Adj. PAT) demonstrated exceptional growth, surging 72% YoY to ₹55 crore.
  • 9M FY26 Performance: For the nine months ended December 31, 2025, revenue stood at ₹1,110 crore, a solid 14% YoY growth. EBITDA grew by 26% YoY to ₹323 crore, and EBITDA margins improved by about 300 basis points YoY to 29%. The most striking growth was observed in Adj. PAT, which demonstrated substantial acceleration, growing an impressive 128% YoY to ₹146 crore.

The Quality: Margin Expansion and Financial Health

The quality of earnings appears to be improving. Margin expansion, evident in both EBITDA and PAT growth outpacing revenue growth, is a key positive. Adjusted ROCE improved to 17.1% for 9M FY26 from 15.0% in FY25, indicating better returns on capital employed. The company's financial leverage has also seen a reduction, with the Net Debt to EBITDA ratio decreasing to 1.4x in 9M FY26 from 1.6x in FY25. Significant investment in assets is also visible, with the Gross Block increasing to ₹2,087 crore in 9M FY26 from ₹1,538 crore in FY22, signalling capacity expansion and future growth potential.

The Grill: Management's Forward Outlook

While no specific analyst 'grill' details are available from the filing, the management's outlook for FY27 is decidedly optimistic. They expressed confidence in a "significantly better FY27," anticipating that operating leverage will drive meaningful improvements in both revenue and EBITDA margins. This forward-looking guidance is underpinned by a strong pipeline, including multiple product launches in the Formulations segment, Novel Chemical Entity (NCE) projects in the CDMO division, expansion of the Specialty API portfolio, progress in the Biologics segment, and the advancement of Recombinant Human Albumin (rHA) with a strategic European partnership.

Risks & Outlook

Key Growth Drivers:

  • Formulations (FDF): Exceptional 50% YoY growth in 3Q FY26, powered by over 100% YoY growth in the EU and strong domestic performance. The launch of the first-in-class NAFLD therapy (NorUDCA), branded NoducaTM, in India is a significant development. Strategic partnerships with large pharma firms also bolster the FDF segment.
  • API: Expansion of capacities supporting non-oncology growth, alongside contributions from key base business products in both oncology and non-oncology portfolios. The Specialty CDMO division shows steady performance.
  • Biologics: Progress in high-value biosimilar pipeline assets and ongoing clinical trials.
  • Product Approvals & Launches: EU approval for Rotigotine, completion of Phase 3 for Ondansetron ER in India, marketing authorization for Rotigotine Transdermal Patch in Europe, and positive Phase 3 results for Ondansetron ER Injection (OERIS). The landmark NorUDCA approval for NAFLD in India is a global first.

Specific Risks:

  • Execution Risk: The success of the FY27 outlook hinges on the timely and effective execution of planned product launches and clinical trial advancements.
  • Regulatory Hurdles: While past approvals have been strong, the pharmaceutical sector inherently faces ongoing regulatory scrutiny in key markets.
  • Competition: The competitive landscape for APIs, formulations, and biosimilars remains intense, requiring continuous innovation and cost efficiency.

The Forward View: Investors should closely monitor the commercialization success of NoducaTM in India, the performance of new launches in the EU, and progress in the Biologics pipeline, particularly rHA, as these will be key indicators for achieving the company's ambitious FY27 targets.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.